PC
TAK icon

Paulson & Co’s Takeda Pharmaceutical TAK Stock Holding History

Paulson & Co’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,727,415
Closed -$86.3M – 42
2021
Q1 		$86.3M Sell
4,727,415
-6,568,431
-58% -$118M 1.98% 13
2020
Q4 		$206M Hold
11,295,846
– – 5.34% 7
2020
Q3 		$202M Sell
11,295,846
-191,059
-2% -$3.48M 6.28% 6
2020
Q2 		$206M Sell
11,486,905
-1,757,806
-13% -$31.6M 6.58% 5
2020
Q1 		$201M Hold
13,244,711
– – 7.67% 4
2019
Q4 		$261M Hold
13,244,711
– – 5.64% 7
2019
Q3 		$228M Hold
13,244,711
– – 4.56% 8
2019
Q2 		$234M Hold
13,244,711
– – 3.98% 7
2019
Q1 		$270M Buy
+13,244,711
New +$267M 5.66% 7

Other funds holding TAK

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Paulson & Co's TAK Position: Q2 2021 in Review

Paulson & Co sold out of Takeda Pharmaceutical (TAK) in Q2 2021, closing a stake of 4,727,415 shares — an estimated $86.3M sold.

Paulson & Co first reported a position in TAK in Q1 2019 and held it in 9 quarters. The position peaked at $270M in Q1 2019. 304 funds tracked by Wall St. Rank hold TAK as of Q2 2021.

  • Paulson & Co reported no remaining Takeda Pharmaceutical position as of Q2 2021 after selling out during the quarter.
  • Paulson & Co sold 4,727,415 Takeda Pharmaceutical shares in Q2 2021, an estimated $86.3M.
  • Paulson & Co first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 9 quarters.
  • Paulson & Co's Takeda Pharmaceutical position peaked at $270M in Q1 2019.
  • 304 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2021.

Based on Paulson & Co's 13F filing for Q2 2021, filed 16 Aug 2021.